Physician

Daniel Michael Geynisman, M.D.

According to 2025 Medicare claims, Daniel Geynisman, M.D. (NPI: 1437343597) practices hematopoietic cell transplantation and cellular therapy in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN, INC (NPI: 1417430166; TIN: 831002191) and primary practice location at 19111-2434. Geynisman is affiliated with the Trinity Health Integrated Care (ACO ID: A3454), participating under the MSSP model.

Geynisman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 235 traditional Medicare patients, billed 663 HCPCS/CPT codes, and received $60,259 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,892 prescription claims across 185 beneficiaries totaling $8,280,168 in drug costs, led by Xtandi (Enzalutamide). Open Payments data shows 42 records totaling $218,047. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $917,113 to $8,280,168. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.